SPECIAL REPORT

A Brownstone Research Publication

The Great Reset Profit BlueprintBy Jeff Brown

2The Near Future Report

Special Report 2021

Thank you for becoming a reader of The Near Future Report. You now have access to all the special reports outlined in my Great Reset investment presentation. To access your entire report library, simply go right here.

In this short “action sheet,” I’ll show you all of the stocks I’m recommending. For specific details on each investment, please refer to all the individual reports.

Recommendation Action to Take

Fiserv (FISV) Fiserv (FISV) is a buy up to $123

My #1 Fintech Play for the Great Reset: How to Triple Your Money as Cash Goes Digital

Important: These are stocks that I recommend readers avoid at all costs. Their valuations are either too high to justify investing or they are stodgy incumbents that have failed to innovate. Either way, these are stocks we want to steer clear of.

Toxic Tech #1: Intel (INTC) Toxic Tech #4: Coupa Software (COUP)

Toxic Tech #2: International Business Machine (IBM) Toxic Tech #5: Zscaler (ZS)

Toxic Tech #3: Zoom Video Communications (ZM) Toxic Tech #6 (Bonus): Fastly (FSLY)

Toxic Tech: 5 Tech “Darlings” to Dump Right Now

Recommendation Action to Take

Voatz Inc. Add Voatz to our watchlist.

Elected by Blockchain: The Private Company Revolutionizing the Way Americans Vote

Recommendation Action to Take

Salesforce (CRM) Salesforce (CRM) is a buy up to $230

Palo Alto Networks (PANW) Palo Alto (PANW) is a buy up to $350

Qorvo (QRVO) Qorvo (QRVO) is a buy up to $170

Corning (GLW) Corning (GLW) is a buy up to $40

Arista Networks (ANET) Arista Networks (ANET) is a buy up to $300

Bonus: Square (SQ) Square (SQ) is a buy up to $210

The New Economy: 5 Stocks That Will Soar in the “Post-COVID” World

3The Near Future Report

To contact us, call toll free Domestic/International: 1-888-512-0726, Mon-Fri: 9am-5pm ET or email memberservices@brownstoneresearch.com.

© 2021 Brownstone Research, 55 NE 5th Avenue, Delray Beach, FL 33483. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from the publisher.

Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. It is not designed to meet your personal situation—we are not financial advisors nor do we give personalized advice. The opinions expressed herein are those of the publisher and are subject to change without notice. It may become outdated and there is no obligation to update any such information.

Recommendations in Brownstone Research publications should be made only after consulting with your advisor and only after reviewing the prospectus or financial statements of the company in question. You shouldn’t make any decision based solely on what you read here.

Brownstone Research writers and publications do not take compensation in any form for covering those securities or commodities.

Brownstone Research expressly forbids its writers from owning or having an interest in any security that they recommend to their readers. Furthermore, all other employees and agents of Brownstone Research and its affiliate companies must wait 24 hours before following an initial recommendation published on the Internet, or 72 hours after a printed publication is mailed.

Recommendation Action to Take

BioMarin Pharmaceutical (BMRN) BioMarin (BMRN) is a buy up to $91

The Top BioTech Buyout Candidate: The 2,200% Secret